GSK cancer head Hoos exits, takes top role at biotech ScorpionGlaxoSmithKline’s head of oncology Axel Hoos has resigned from the company, and will take up a new role Share XGSK cancer head Hoos exits, takes top role at biotech Scorpionhttps://pharmaphorum.com/news/gsk-cancer-head-hoos-exits-takes-top-role-at-biotech-scorpion/
Imugene HER2 vaccine hits target in stomach cancer trialA peptide vaccine developed by Australia’s Imugene has reduced tumour size in around half of patients with HER2-positive Share XImugene HER2 vaccine hits target in stomach cancer trialhttps://pharmaphorum.com/news/imugene-her2-vaccine-hits-target-in-stomach-cancer-trial/
Merck pulls Keytruda’s FDA nod for third-line stomach cancerMerck & Co will voluntarily withdraw a US marketing approval for cancer immunotherapy blockbuster Keytruda in gastric cancer, Share XMerck pulls Keytruda’s FDA nod for third-line stomach cancerhttps://pharmaphorum.com/news/merck-pulls-keytrudas-fda-nod-for-third-line-stomach-cancer/
Real Chemistry hires new global chief inclusion and health equity officerGlobal health innovation company Real Chemistry has announced the appointment of Mary Stutts to lead its diversity, equity Share XReal Chemistry hires new global chief inclusion and health equity officerhttps://pharmaphorum.com/news/real-chemistry-hires-new-global-chief-inclusion-and-health-equity-officerd/
Exelixis’ Cabometyx misses survival target in liver cancer trialExelixis has suffered a blow to its efforts to expand the use of Cabometyx into additional indications after Share XExelixis’ Cabometyx misses survival target in liver cancer trialhttps://pharmaphorum.com/news/exelixis-cabometyx-misses-survival-target-in-liver-cancer-trial/
Libtayo gets a double with EU approvals in skin, lung cancerSanofi and Regeneron’s checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for Share XLibtayo gets a double with EU approvals in skin, lung cancerhttps://pharmaphorum.com/news/libtayo-gets-a-double-with-eu-approvals-in-skin-lung-cancer/
AbbVie jumps on the BCMA train, opting into TeneoOne buyAfter dipping its toe into the BCMA water with an option to codevelop a bispecific antibody developed by Share XAbbVie jumps on the BCMA train, opting into TeneoOne buyhttps://pharmaphorum.com/news/abbvie-jumps-on-the-bcma-train-opting-into-teneoone-buy/
Arcus preps more phase 3 trials for TIGIT antibody, as Gilead opt-in beckonsArmed with a positive mid-stage trial readout in lung cancer, Arcus Biosciences will expand a phase 3 programme Share XArcus preps more phase 3 trials for TIGIT antibody, as Gilead opt-in beckonshttps://pharmaphorum.com/news/arcus-preps-more-phase-3-trials-for-tigit-antibody-as-gilead-opt-in-beckons/
AZ, HutchMed’s savolitinib gets 1st approval in China for NSCLCAstraZeneca and HutchMed have claimed their first approval – in China – for cMET inhibitor savolitinib as a Share XAZ, HutchMed’s savolitinib gets 1st approval in China for NSCLChttps://pharmaphorum.com/news/az-hutchmeds-savolitinib-gets-1st-approval-in-china-for-nsclc/
In a class first, Merck’s Keytruda extends survival in cervical cancerMerck & Co’s Keytruda has become the first checkpoint inhibitor to help patients with advanced cervical cancer live Share XIn a class first, Merck’s Keytruda extends survival in cervical cancerhttps://pharmaphorum.com/news/in-a-class-first-mercks-keytruda-extends-survival-in-cervical-cancer/
BioNTech takes its first cancer vaccine into phase 2It would be easy to forget that back in 2019, BioNTech was an early-stage biotech firmly focused on Share XBioNTech takes its first cancer vaccine into phase 2https://pharmaphorum.com/news/biontech-takes-its-first-cancer-vaccine-bnt111-into-phase-2/
BMS pays $650m upfront for Eisai’s first ADC candidate for cancerJapan’s Eisai has hit the jackpot with its first ever antibody-drug conjugate (ADC) drug candidate, attracting a licensing Share XBMS pays $650m upfront for Eisai’s first ADC candidate for cancerhttps://pharmaphorum.com/news/bms-pays-650m-upfront-for-eisais-first-adc-candidate-for-cancer/
Gilead combs Shoreline for NK cell therapies in $2.3bn allianceGilead Sciences’ cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging Share XGilead combs Shoreline for NK cell therapies in $2.3bn alliancehttps://pharmaphorum.com/news/gilead-combs-shoreline-for-nk-cell-therapies-in-2-3bn-alliance/
Ambrx tries another IPO as it chases down HER2 rivalsCalifornia biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock Share XAmbrx tries another IPO as it chases down HER2 rivalshttps://pharmaphorum.com/news/ambrx-tries-another-ipo-as-it-chases-down-her2-rivals/
GSK joins anti-TIGIT push with $625m upfront iTeos dealGlaxoSmithKline has staked a claim to the fast-moving category of cancer therapies targeting the TIGIT immune checkpoint, agreeing Share XGSK joins anti-TIGIT push with $625m upfront iTeos dealhttps://pharmaphorum.com/news/gsk-joins-ant-tigit-push-with-625m-upfront-iteos-deal/
